SEARCH FOR AND IDENTIFICATION OF MOLECULAR TARGETS OF ANGUCYCLINE ANTIBIOTIC LANDOMYCIN E IN HUMAN TUMOR CELLS
DOI: http://dx.doi.org/10.30970/sbi.0601.194
Abstract
Study of cellular and molecular mechanisms of anticancer activity of novel perspective angucycline antibiotic landomycin E was carried out. It was revealed that this compound uses mechanisms of apoptosis induction in tumor cells that differ from such mechanisms used by structurally related drug doxorubicin which is widely applied in clinics. In particular, landomycin E blocks cells in G1 phase of cell cycle, and this action is mediated by the reactive oxygen species. Such G1-specificity of landomycin E action of can be of great importance in chemotherapy, since it is known that cancer stem cells which are responsible for recurrent tumors, are staying mainly in G0/G1 phase, and, thus, are insensitive to most anticancer drugs. Application of Western-blot analysis for studying potential intracellular targets of the landomycin E action allowed identifying procaspase-7 as a targeted effector apoptotic protein. There are no other cases of direct activation of this enzyme by the anticancer drugs described in literature till now. Thus, such a unique mechanism of anticancer activity might allow landomycin E to kill tumor cells effectively even in the absence of other key enzymes involved in apoptosis, such as caspase-3. Taking into consideration high antineoplastic potential of landomycin E and unique mechanism of its action, this antibiotic could be recommended as anticancer drug of second line defense at treatment of cancer patients.
Keywords
Full Text:
PDF (Українська)References
1. Мацелюх Б.П., Лаврінчук В.Я. Одержання і характеристика мутантів Streptomyces globisporus 1912, дефектних по біосинтезу ландоміцину Е. Мікробіол журн, 1999; 61: 22-27. | |
| |
2. Панчук Р., Кориневська А., Осташ Б. та ін. Дослідження механізмів дії ландоміцину Е на клітини ссавців. Вісн. Львів. ун-ту. Сер. біол, 2004; 35: 54-59. | |
| |
3. Поліщук Л.В., Ганусевич І.І., Мацелюх Б.П. Вивчення протипухлинної дії антибіотиків, що продукуються Streptomyces globisporus 1912, на моделі карциноми Ґерена щурів. Мікробіол журн, 1996; 58: 55-58. | |
| |
4. Фільченков О.О., Стойка Р.С. Апоптоз і рак: від теорії до практики. Тернопіль: ТДМУ "Укрмедкнига", 2006. - 524 с. | |
| |
5. Henkel T., Rohr J., Beale J.M., Schwenen L. Landomycins, new angucycline antibiotics from Streptomyces sp. I. structural studies on landomycins A-D. J. Antibiot, 1990; 43: 492-503. | |
| |
6. Kamohara Y., Haraguchi N., Mimori K. et al. The search for cancer stem cells in hepatocellular carcinoma. Surgery, 2008; 144(2): 119-124. | |
| |
7. Kim R., Tanabe K., Uchida Y. et al. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol, 2002; 50(5): 343-352. | |
| |
8. Korynevska A., Heffeter P., Matselyukh B. et al. Mechanisms underlying the anticancer activities of the angucycline landomycin E. Biochem. Pharmacol, 2007; 74(12): 1713-1726. | |
| |
9. Korynevska A.V., Matselyukh B.P., Stoika R.S. In vitro study of landomycin E antitumor activity. Експеримент. онкологія, 2003; 25: 98-105. | |
| |
10. Laemmli U. Cleavage of structural protein during the assembly of the head of bacteriofage T4. Nature, 1970; 227: 680-684. | |
| |
11. Ling Y.H., el-Naggar A.K., Priebe W., Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol. Pharmacol, 1996; 49(5): 832-841. | |
| |
12. Luzhetskyy A., Zhu L., Gibson M. et al. Generation of novel landomycins M and O through targeted gene disruption. Chembiochem, 2005; 6(4): 675-678. | |
| |
13. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod, 2007; 70(3): 461-477. | |
| |
14. Panchuk R.R. Signaling pathways involved in apoptosis induced by novel angucycline antibiotic landomycin E in Jurkat T leukemia cells. Biopolymers and Cell, 2011; 27(2): 124-131. | |
| |
15. Peterson G.L. А simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochemistry, 1977; 83(2): 346-358. | |
| |
16. Rohr J., Hertweck C. Comprehensive Natural Products II−Chemistry and Biology; Mander, L. and Liu, H.-W., Eds.; Elsevier: Oxford. 2010; 1: 227-303. | |
| |
17. Rohr J., Thiericke R. Angucycline group antibiotics. Nat. Prod. Rep, 1992; 9: 103-137. | |
| |
18. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 1994; 15: 78(1): 67-74. | |
| |
19. Vakifahmetoglu-Norberg H., Zhivotovsky B. The unpredictable caspase-2: what can it do? Trends Cell Biol, 2010; 20(3: 150-159. | |
| |
20. Warr M.R., Shore G.C. Small-molecule Bcl-2 antagonists as targeted therapy in oncology. Curr. Oncol, 2008; 15(6): 256-261. | |
| |
21. Zhukov N.V., Tjulandin S.A. Targeted therapy in the treatment of solid tumors: practice contradicts theory. Biochemistry (Mosc), 2008; 73(5): 605-618. |
Refbacks
- There are currently no refbacks.
Copyright (c) 2012 Studia biologica
This work is licensed under a Creative Commons Attribution 4.0 International License.